Samsung Biologics Co.,Ltd. in 3 stories
The narratives 207940.KS currently appears in, with its side and exposure in each.
Bull side
3 stories- America Imports the World's Drug Prices
207940.KS in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Samsung Biologics combines large-scale biologics manufacturing with Samsung Bioepis's biosimilars, supporting lower-cost alternatives across blockbuster categories.
- Drug Manufacturing De-Risks From China
207940.KS in “Drug Manufacturing De-Risks From China”
FadingExposure: not rated yetWestern drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.
Its large-scale Korean biologics plants offer global pharmaceutical customers a credible non-Chinese alternative.
- The Patent Cliff Sparks a Biotech Land Grab
207940.KS in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Demand for outsourced production of antibodies and other complex biologics should rise as acquirers seek to scale newly purchased pipelines quickly.
Bear side
0 storiesNo bear-side stories for 207940.KS yet.